First Light Asset Management LLC Trims Position in Heron Therapeutics Inc (NASDAQ:HRTX)

Share on StockTwits

First Light Asset Management LLC decreased its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 1.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,723 shares of the biotechnology company’s stock after selling 14,243 shares during the period. Heron Therapeutics accounts for approximately 2.8% of First Light Asset Management LLC’s portfolio, making the stock its 13th largest holding. First Light Asset Management LLC’s holdings in Heron Therapeutics were worth $20,425,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Marshall Wace LLP lifted its stake in shares of Heron Therapeutics by 33,842.9% during the second quarter. Marshall Wace LLP now owns 68,904 shares of the biotechnology company’s stock valued at $1,281,000 after buying an additional 68,701 shares during the period. Vanguard Group Inc. lifted its stake in shares of Heron Therapeutics by 5.2% during the second quarter. Vanguard Group Inc. now owns 6,744,858 shares of the biotechnology company’s stock valued at $125,387,000 after buying an additional 330,351 shares during the period. AMP Capital Investors Ltd lifted its stake in shares of Heron Therapeutics by 30.5% during the second quarter. AMP Capital Investors Ltd now owns 50,898 shares of the biotechnology company’s stock valued at $938,000 after buying an additional 11,906 shares during the period. BlackRock Inc. lifted its stake in shares of Heron Therapeutics by 0.9% during the second quarter. BlackRock Inc. now owns 4,901,392 shares of the biotechnology company’s stock valued at $91,116,000 after buying an additional 42,657 shares during the period. Finally, US Bancorp DE lifted its stake in shares of Heron Therapeutics by 75.6% during the second quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 1,769 shares during the period.

Several equities analysts recently issued reports on HRTX shares. Northland Securities reissued a “buy” rating and set a $55.00 price objective on shares of Heron Therapeutics in a research note on Monday, August 5th. BidaskClub raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a research note on Monday, August 5th. Finally, Evercore ISI reaffirmed a “buy” rating and set a $75.00 price target on shares of Heron Therapeutics in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Heron Therapeutics presently has a consensus rating of “Buy” and an average target price of $52.67.

NASDAQ:HRTX opened at $19.41 on Friday. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04. Heron Therapeutics Inc has a fifty-two week low of $15.68 and a fifty-two week high of $33.20. The firm’s 50 day moving average is $18.20 and its two-hundred day moving average is $20.00.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. The company had revenue of $36.66 million for the quarter, compared to the consensus estimate of $31.04 million. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. On average, analysts forecast that Heron Therapeutics Inc will post -2.73 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: What causes a yield curve to invert?

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lynas  Stock Price Crosses Above Two Hundred Day Moving Average of $1.70
Lynas Stock Price Crosses Above Two Hundred Day Moving Average of $1.70
Genprex Inc  Short Interest Up 13.4% in September
Genprex Inc Short Interest Up 13.4% in September
Livexlive Media Inc  Short Interest Up 13.0% in September
Livexlive Media Inc Short Interest Up 13.0% in September
Kinsale Capital Group Inc  Expected to Announce Quarterly Sales of $76.24 Million
Kinsale Capital Group Inc Expected to Announce Quarterly Sales of $76.24 Million
YOYOW Reaches 1-Day Volume of $131,757.00
YOYOW Reaches 1-Day Volume of $131,757.00
JSECOIN  Hits Market Cap of $128,338.00
JSECOIN Hits Market Cap of $128,338.00


© 2006-2019 Ticker Report